Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2014 Mar 15;7(4):1299–1313.

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

IJCEP Copyright © 2014

PMC Copyright notice

VPA suppresses sorafenib-induced cell migration of TGF-β-sensitized cells. Cells were pretreated with TGF-β for 24 h and then treated with 0.5 μM sorafenib with or without VPA or LY294002 (LY). A. Transwell migration assays revealed that the rate of cell migration was increased by low dose sorafenib, which was enhanced by TGF-β. Combination treatment with sorafenib and VPA or LY294002 (LY) significantly inhibited migration. B. Wound healing assays of HepG2 cells showed that treatment with low dose sorafenib accelerated wound closure, which was enhanced by TGF-β. Combination treatment with VPA or LY294002 (LY) significantly reduced migration. Representative images of wounded cell monolayers are shown (bar; 100 μm). Data represent the means ± SD of triplicate experiments (**P<0.05).